NGM - NGM Biopharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.15B
Enterprise Value 3783.14M
Trailing P/E N/A
Forward P/E 1-14.13
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)9.66
Price/Book (mrq)3.31
Enterprise Value/Revenue 36.59
Enterprise Value/EBITDA 6-115.24

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3∞%
S&P500 52-Week Change 30.90%
52 Week High 318.75
52 Week Low 312.00
50-Day Moving Average 314.28
200-Day Moving Average 314.50

Share Statistics

Avg Vol (3 month) 398.43k
Avg Vol (10 day) 3105.76k
Shares Outstanding 566.02M
Float 26.68M
% Held by Insiders 129.27%
% Held by Institutions 141.69%
Shares Short (Jul 31, 2019) 4802.54k
Short Ratio (Jul 31, 2019) 49.78
Short % of Float (Jul 31, 2019) 42.25%
Short % of Shares Outstanding (Jul 31, 2019) 41.22%
Shares Short (prior month Jun 28, 2019) 4732.32k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -7.82%
Operating Margin (ttm)-12.17%

Management Effectiveness

Return on Assets (ttm)-2.85%
Return on Equity (ttm)-3.59%

Income Statement

Revenue (ttm)118.83M
Revenue Per Share (ttm)5.84
Quarterly Revenue Growth (yoy)14.60%
Gross Profit (ttm)12.95M
EBITDA -6.8M
Net Income Avi to Common (ttm)-9.29M
Diluted EPS (ttm)-0.46
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)362.19M
Total Cash Per Share (mrq)5.5
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)9.53
Book Value Per Share (mrq)5.25

Cash Flow Statement

Operating Cash Flow (ttm)-18.72M
Levered Free Cash Flow (ttm)3.17M